# Neutrophil-to-Lymphocyte Ratio Dynamics From Pre-diagnosis to End-Stage Amyotrophic Lateral Sclerosis (ALS): A Case Study on Association With Progression and Clinical Events

**Authors:** Kevin De Jesus-Morales, Wilfredo De Jesús-Rojas, Marcos J Ramos-Benitez

PMC · DOI: 10.7759/cureus.58109 · 2024-04-12

## TL;DR

This study tracks how the neutrophil-to-lymphocyte ratio (NLR) changes over 13 years in a patient with ALS, showing its link to disease progression and key clinical events.

## Contribution

The first detailed characterization of NLR dynamics from pre-diagnosis to end-stage ALS, linking it to clinical deterioration and events.

## Key findings

- NLR increased significantly with symptom onset and remained elevated during disease progression.
- NLR normalized during edaravone therapy, suggesting a potential treatment effect.
- NLR correlated with clinical deterioration, decreased pulmonary function, and key clinical events.

## Abstract

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative condition characterized by the progressive degeneration of motor neurons, resulting in muscle weakness and paralysis. The neutrophil-to-lymphocyte ratio (NLR) has emerged as a potential marker for monitoring disease severity and progression in ALS, yet longitudinal analyses of NLR are limited. Our study conducts an in-depth examination of NLR dynamics from before diagnosis through the disease's progression to its end stage. We analyze the case of a 56-year-old Puerto Rican male with ALS, tracking his NLR over 13 years - six years before and seven years after his diagnosis - alongside assessments of clinical symptoms and lung function. Our findings indicate that NLR values were initially normal but significantly increased with the onset of symptoms. NLR remained elevated above the normal range, with a notable exception during a period of edaravone therapy when levels normalized. The study demonstrates a clear elevation in NLR associated with ALS progression and critical clinical events, such as symptom onset, diagnosis, and the initiation of respiratory support. This research is, to our knowledge, the first to provide a detailed characterization of NLR changes from the pre-diagnostic phase to end-stage ALS, showing its correlation with clinical deterioration, decreased pulmonary function, and key clinical events. Our results contribute to the body of evidence on NLR's role in ALS while enhancing our understanding of ALS's natural progression.

## Linked entities

- **Chemicals:** edaravone (PubChem CID 4021)
- **Diseases:** Amyotrophic Lateral Sclerosis (MONDO:0004976), ALS (MONDO:0004976)

## Full-text entities

- **Diseases:** neurodegenerative condition (MESH:D019636), paralysis (MESH:D010243), ALS (MESH:D000690), muscle weakness (MESH:D018908)
- **Chemicals:** edaravone (MESH:D000077553)

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC11088800/full.md

---
Source: https://tomesphere.com/paper/PMC11088800